Interleukin-18 (IL-18) is a pleiotropic proinflammatory cytokine expressed mainly in Kupffer cells and activated macrophages and is associated particularly with inflammation in the vascular wall. 1 Expression of IL-18 has been detected in human atherosclerotic plaques and has been associated with plaque progression and plaque vulnerability. 2, 3 Epidemiological studies have shown that plasma levels of IL-18 are predictive of future cardiovascular events both in healthy individuals and patients with coronary artery disease. [4] [5] [6] Several studies have shown that arterial functional and structural characteristics and endothelial/inflammatory activation are important determinants of cardiovascular performance and predictors of risk. [7] [8] [9] [10] [11] [12] Low-grade inflammation has been associated both through causal 13 and associative 14, 15 relationships with functional and structural changes in the properties of the arterial wall.
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Although associations between circulating IL-18 level and some arterial functional and structural parameters have been reported previously, findings have been inconclusive. [16] [17] [18] [19] [20] [21] [22] Accordingly, in the present study, we sought to investigate whether IL-18 concentration in blood is associated with an altered function and structure of the arterial system in subjects without overt cardiovascular disease. For this purpose, we employed a thorough arterial approach including measures of arterial stiffness and wave reflections, endothelium-dependent vasodilation, and arterial wall thickness, as well as measurements of circulating levels of certain inflammatory markers/ mediators.
methodS
Study population. Subjects were men consecutively enrolled from a large cohort followed in our Department for Arterial Function Studies. All participants were screened for sociodemographic data and risk factors for cardiovascular disease and Background increased levels of interleukin-18 (iL-18) have been related to plaque progression and vulnerability and cardiovascular outcomes. arterial functional and structural characteristics and endothelial/inflammatory activation are important determinants of cardiovascular performance and predictors of risk. We investigated whether iL-18 is a determinant of global arterial function and early structural changes in men.
We evaluated arterial structural and functional characteristics (carotid-femoral pulse wave velocity (pWV), central aortic pressures, wave reflection indexes, flow-mediated dilation of the brachial artery, and common carotid intima-media thickness (iMT)) and we measured systemic inflammatory markers in 97 men (mean age 57.8 ± 8.6 years) without manifest cardiovascular/atherosclerotic disease.
reSultS
Multivariable analysis adjusting for age, mean pressure, other risk factors, high-sensitivity C-reactive protein (hsCRp), and treatment showed independent associations between iL-18 level and carotid-femoral pWV (P < 0.01) and iMT (P = 0.03). On the other hand, no relationship between iL-18 and flow-mediated dilation, central pressures or augmentation index (aix) was found. The combination of higher iL-18 level with higher carotid-femoral pWV and carotid iMT values showed greater effect on 10-year risk of a cardiovascular event.
original contributions IL-18, Arterial Functional/Structural Associations were comprehensively evaluated with medical history, physical examination, and electrocardiogram. In the present study, patients with a history of coronary artery disease, stroke, or peripheral artery disease were excluded, because circulating IL-18 levels can be substantially modified in such patients. 23, 24 Consequently, the study population comprised 97 men (mean age 57.8 ± 8.6).
Using the Framingham-based Adult Treatment Panel III risk assessment tool, an estimate of 10-year risk for coronary heart disease was calculated. 25 These values were further categorized as low (10-year risk <10%), intermediate (10-year risk of 10-20%), and high (10-year risk >20%).
Study design. Subjects had fasted for at least 6 h and had abstained from caffeine, ethanol, and flavonoid-containing beverages intake for at least 12 h before each session. All vascular studies were performed in the morning between 8 and 10 am, in a quiet, temperature-controlled room at 23 °C. Before the vascular examination, brachial blood pressure measurements were taken using an oscillometric device (Omron M4-I, CE 0197; Omron, Hoofddorp, the Netherlands). Blood pressure was measured twice on the right arm and the average of the two blood pressure values was used in the analyses. After a 20-min rest period, measurements for evaluation of aortic stiffness, pulse wave analysis, carotid wall thickness, and endothelial function of conduit brachial artery were taken in the supine position, in this fixed order. The study complies with the Declaration of Helsinki. The study protocol was approved by our institutional research ethics committee and all subjects gave informed consent.
Evaluation of aortic elastic properties. Pulse travels at a higher velocity in a stiff aorta. Carotid-femoral pulse wave velocity (PWV), an established index of aortic stiffness, was calculated from measurements of pulse transit time and the distance traveled between two recording sites (PWV equals distance in meters divided by transit time in seconds) with a validated noninvasive device (Complior; Artech Medical, Pantin, France), as previously described. 9, 13, 14 Two different pulse waves were obtained simultaneously at two sites (at the base of the neck for the common carotid and over the right femoral artery) with two transducers. Distance was defined as the distance from the suprasternic notch to femoral artery minus the distance from the carotid artery to the suprasternic notch.
Measurement of wave reflection indexes. Central (aortic) blood pressures and augmentation index (AIx), a composite index of wave reflections and arterial stiffness, were calculated using a validated, commercially available system (SphygmoCor; AtCor Medical, Sydney, Australia), which employs the principle of applanation tonometry, as previously described. 10, 11, 13, 14 Augmented pressure (AP) is the pressure added to the incident wave by the returning reflected one and represents the pressure boost with which the left ventricle must cope at systole. AIx was calculated as the augmented pressure divided by pulse pressure and was expressed as a percentage. Large values of AIx indicate increased wave reflection from the periphery and/or earlier return of the reflected wave as a result of increased PWV (owing to increased arterial stiffness) and vice versa. Because AIx is influenced by changes in heart rate, 26 it was also accordingly corrected. AIx values, both unadjusted and adjusted at a heart rate of 75 beats/min (AIx@75) are presented in Table 1 .
Evaluation of endothelial function. Flow-mediated dilatation (FMD) of the brachial artery is predominantly dependent on endothelial nitric oxide release and can be used as an estimate of endothelial function. Resting and postocclusion arterial diameters and flows, reactive hyperemia (the stimulus for the postocclusion diameter response) and FMD of the conduit brachial artery were determined as previously described, 7, 8 by using a high-resolution, linear-array ultrasonic transducer of 7.5-10.5 MHz (Sonos 5500; Hewlett-Packard, Andover, MA). FMD was calculated as the percent change of brachial artery diameter from baseline: FMD (%) = ((postocclusion diameter−resting diameter)/resting diameter) × 100.
All measurements were made by the same investigator (K.A.). The repeatability coefficient was previously calculated for FMD measurements in our Unit in a group of 10 subjects measured on two occasions. The British Standard Institution formula, i.e., repeatability coefficient = 2√ ∑di/N, where N is the sample size and di is the difference between the two measurements in a pair, was used. The repeatability coefficient value for FMD was 2.06%.
Carotid IMT measurement. Intima-media thickness (IMT) of the right and the left common carotid arteries, a marker of subclinical atherosclerosis, 12, 15 was measured in the 1-cm segment proximally to the carotid dilation with B-mode ultrasonography, by using the same ultrasonic transducer and device as described for the FMD study. In brief, three measurements of the maximal IMT in the far wall were averaged. For each patient, mean common carotid IMT was calculated as the average of six measurements (three in the right and three in the left common carotid artery). Plaque was defined as a clearly identified area of focal increased thickness (≥1 mm) of the intima-media layer. The carotid plaques were excluded while measuring IMT.
Laboratory measurements. Immediately after acquisition of venous blood, plasma or serum was separated by centrifugation (3,000g at 4 °C for 15 min), placed in aliquots, and stored at −70 °C. High-sensitivity C-reactive protein (hsCRP) was measured by immunonephelometry (Dade Behring, Marburg, Germany). High-sensitivity IL-6 and IL-18 (BioSource, Camarillo, CA) were measured using enzyme-linked immunosorbent assay.
Statistical analysis.
Results are presented as mean ± s.d. Because of skewed distributions, the natural logarithmic transformation was performed for triglycerides, fasting blood glucose, hsCRP, IL-6, and IL-18. Univariate analysis was performed for determinants of FMD, AIx, PWV, and carotid IMT.
original contributions
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The abovementioned unadjusted associations of aortic function and structure markers with IL-18 and IL-6 levels may have been confounded by variables such as age, blood pressure, heart rate, smoking habits, body mass index, blood glucose, total triglycerides, high-density lipoprotein, and use of angiotensin-converting enzyme inhibitors/angiotensin-II type-1 receptor blockers, and statins by the participants. Therefore, we applied multiple regression analysis for PWV and IMT to adjust for the aforementioned potential confounders. In these models, arterial characteristics (PWV or IMT) were considered as the dependent variable, and IL-18 (models 1 and 3) or IL-6 (models 2 and 4) were considered as the main independent variables. Furthermore, since hsCRP-an established index of subclinical inflammation-has been shown in previous studies to correlate with impaired arterial elastic properties, 14 we introduced hsCRP as an independent variable in the models, in order to investigate whether IL-6 and IL-18 are associated with arterial characteristics beyond the hsCRP.
In order to investigate the impact of IL-18 level on 10-year risk of a cardiovascular event (%), we created the hierarchical model stratified by PWV and IMT values. On the basis of the median IL-18 (173.45 pg/ml) our population was divided into subjects with high-(n = 48) and low-(n = 49) IL-18 concentrations. Similarly, our population was divided according to the median carotid-femoral PWV (7.90 m/s) and median carotid IMT (0.82 mm) into those with high (n = 48) and low (n = 49) values. We used one-way analysis of variance to detect significant differences in 10-year risk of a cardiovascular event (%) between the study subgroups. Comparisons between the study subgroups were performed using the Tukey post hoc test, if the overall F test was significant. Adjustments for established confounders (age, metabolic profile) were made by analysis of covariance.
To further investigate whether an interaction between IL-18 and PWV or IMT could influence 10-year risk of a cardiovascular event (%) a general linear model for cardiovascular risk was analyzed with the following parameters: age, IL-18, PWV, or IMT and the interaction variable IL-18 × PWV or IL-18 × IMT. Statistical significance was defined as P < 0.05. All statistical analyses were performed with the use of SPSS 13.0 (SPSS, Chicago, IL).
reSultS

Subject characteristics
A total of 97 subjects with mean age of 58 years (range 40-76) were studied. The characteristics of the study population are shown in Table 1 .
correlations between arterial markers, clinical characteristics, and inflammation
Univariate analysis Arterial markers and clinical characteristics: FMD was inversely related to age (r = −0.20; P = 0.03) and 10-year risk of a cardiovascular event (%) (r = −0.19; P = 0.03). There was no correlation between FMD and systolic and diastolic pressures. PWV was positively related to age (r = 0.26; P < 0.01), systolic pressure (r = 0.43; P < 0.01), diastolic pressure (r = 0.25; P = 0.02), and plasma glucose (r = 0.24; P = 0.03) ( Table 2) . AIx and AIx@75 were positively related to age (r = 0.32; P = 0.001 and r = 0.29; P < 0.01, respectively), mean pressure (r = 0.28; P < 0.01 and r = 0.26; P < 0.01, respectively), and systolic pressure (r = 0.21; P = 0.02 and r = 0.19; P = 0.04, respectively). IMT was significantly and positively related to age (r = 0.44; P < 0.001), systolic pressure (r = 0.30; P < 0.01), and fasting blood glucose (r = 0.45; P < 0.001) ( Table 2) .
Arterial markers and inflammation: FMD correlated inversely with IL-6 (r = −0.22; P = 0.03). In contrast, there was no correlation between FMD and level of IL-18 (r = −0.13; P = 0.22) or hsCRP (r = −0.14; P = 0.18). There were significant positive relationships between PWV and log hsCRP (r = 0.21; P = 0.04), log IL-6 (r = 0.26; P < 0.01) and log IL-18 (r = 0.37; P < 0.001). On the other hand, AIx and AIx@75 did not correlate with IL-6 (r = 0.09 and r = 0.07, respectively, all P > 0.05) original contributions
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or IL-18 levels (r = 0.10 and r = 0.08, respectively, all P > 0.05). Furthermore, we did not observe any significant correlation between central (aortic) pressures or central (aortic) augmented pressure and IL-6 or IL-18 levels (all P > 0.05). Finally, IMT correlated significantly with log IL-6 (r = 0.36; P < 0.001) and log IL-18 (r = 0.25; P < 0.01), but there was no correlation between IMT and log CRP (r = 0.02; P = 0.83).
Multivariable analysis
The results of the multiple regression models in terms of regression coefficients are shown in Tables 3 and 4 . PWV exhibited a significant independent positive association with both IL-18 and IL-6, indicating deterioration in vascular stiffness with increasing IL levels. In these models, IL-18 and IL-6 predicted a 3.3 and 1.2% of PWV variability, respectively. IMT exhibited significant positive associations with both IL-18 and IL-6, indicating deterioration in vascular wall structure with increasing IL values. In these models, IL-18 and IL-6 predicted a 0.9 and 2.1% of IMT variability, respectively. cardiovascular risk, arterial markers, and il-18 Figure 1 shows the impact of IL-18 levels in association with PWV and IMT values on 10-year risk of a cardiovascular event (%). Individuals with high IL-18 levels, when these are combined with elevated PWV and/or elevated IMT values, have an elevated 10-year risk of a cardiovascular event (P < 0.01 for both).
The interaction between IL-18 and PWV and between IL-18 and IMT were not significantly associated with 10-year risk of a cardiovascular event (%) (P = 0.74 and P = 0.48, respectively).
diScuSSion
Our study is the first, to the best of our knowledge, to evaluate through a thorough arterial approach the association between IL-18 concentration and functional and early structural arterial changes in men without manifest cardiovascular/atherosclerotic disease. Specifically, IL-18 is an independent determinant of PWV and IMT, whereas there was no association with FMD and central pressures and wave reflection indexes. Our observations highlight the role of IL-18 as a marker of arterial disease and its correlations with measures of arterial function. In both models, age, systolic BP, heart rate, smoking habits (pack-years), body mass index, fasting blood glucose, total triglycerides, HDL cholesterol, hsCRP, and use of angiotensinconverting enzyme inhibitors/angiotensin-II type-1 receptor blockers and statins were introduced as covariates. BP, blood pressure; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; IL-18, interleukin-18. Figure 1 | impact of the relation between interleukin (iL-18) concentrations and (a) carotid-femoral pulse wave velocity (pWV), (b) intima-media thickness (iMT) on 10-year risk of a CV event (%). P value represents probability after adjustment, by analysis of covariance, for age and metabolic profile. *P < 0.01 vs. subjects with low iL-18 concentrations and low pWV or iMT values. CV, cardiovascular event.
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clinical implications
Our study may have important implications. Arterial functional and structural characteristics are important determinants of cardiovascular performance and predictors of risk in several populations. [7] [8] [9] [10] [11] [12] On the other hand, IL-18 has received particular interest because it appears to play a crucial role in atherosclerotic plaque rupture 2 and has a strong predictive value of cardiovascular death in patients with coronary artery disease and even in healthy individuals. 4, 6 Accordingly, associations between IL-18 and functional and early structural changes can be seen in two ways. Given the important predictive value of aortic stiffness for cardiovascular risk and particularly for fatal and nonfatal coronary events, 27, 28 one might infer that the increased cardiovascular risk in high IL-18 levels may be mediated, among other mechanisms, by increased aortic stiffness. Indeed, a stiff aorta increases left ventricular afterload and disturbs myocardial blood flow, thus unbalancing coronary perfusion/myocardial demand equilibrium. 29 Inversely, the increased cardiovascular risk in patients with impaired aortic elastic properties and increased carotid thickness may be mediated, at least partly, by the low-grade inflammation that is induced by high IL-18 levels. 2, 18, 22 Interestingly, our findings suggest that the combination of higher circulating IL-18 levels with an unfavorable profile of arterial structure and function is accompanied by a moderate and high-cardiovascular risk profile. Thus, it could be inferred that in individuals without overt coronary artery disease increased IL-18 concentration may be associated with a higher cardiovascular risk beyond the changes within the arterial wall. Accordingly, increased IL-18 levels could indicate a need for more aggressive antiatherosclerotic management. It should be kept in mind, however, that the design of our study does not allow drawing of conclusions on the exact nature of relationships and further studies are warranted.
Pathophysiological considerations
We 13, 14 and other investigators 30, 31 have recently shown that low-grade inflammation is associated with arterial stiffness. IL-18 by itself may contribute, at least partly, to the deterioration of large artery stiffness by further promoting inflammation. Indeed, the stimulation of cell types with IL-18 induces proinflammatory cytokines such as IL-6, adhesion molecules such as intercellular adhesion molecule-1, and enzymes capable of degrading extracellular matrix (matrix metalloproteinases). 3, 32 The design of our study, however, does not allow us to determine whether there is a causal relationship between the increased IL-18 level and aortic stiffness.
There was no association between IL-18 concentration and central (aortic) pressures and indexes of wave reflections, such as AIx. Although often arterial stiffness and wave reflection measures often change in parallel, this is not always the case. 13, 14, 30 AIx is a composite marker of wave reflections that integrates the amount of the wave that is reflected back to the aorta (depending on the tone of the resistance arteries, which are the main peripheral reflecting sites) and the velocity of this reflected wave (which, in turn, depends on arterial stiffness). 9, 10, 13 Our data suggest that although IL-18 is related to increased large artery stiffness, the decreased amplitude of the reflected wave due to peripheral inflammation-induced vasodilation leads to a neutral effect on composite indexes such as AIx. This is corroborated by studies showing a divergent effect of PWV and AIx in acute inflammation 13 and absence of correlation between inflammatory markers and wave reflection indexes, despite a positive correlation with PWV, in the chronic setting. 14, 30, 31 Given the tight interrelations between inflammation and endothelial function, 33 one would predict that IL-18 would correlate strongly with endothelial dysfunction. However, although in a small clinical study in patients with unstable angina IL-18 level was related to endothelial function, 17 in other studies in healthy individuals a neutral relationship was shown. 34 The results of these latter studies together with our finding imply that any predictive value of IL-18 in these settings does not necessarily depend on the induction of endothelial dysfunction.
Several lines of evidence support the association between IL-18 level and carotid thickness found in the present study. 16, 18, 19 Experimental data suggest that IL-18 stimulates 35 and, via induction of interferon-γ secretion, promotes collagen and lipid deposition. 36 IL-18 is highly expressed in human carotid atherosclerotic plaques compared with normal control arteries, predominantly localized and upregulated in plaque macrophages. 2, 3 Regarding aortic stiffness, our findings extend to broader population previous observations in specific populations that included patients with diabetes, 18 chronic kidney disease, 22 systemic lupus erythematosus, 20 and older men with metabolic syndrome. 37 Regarding IMT, our findings are in line with a previous study showing a significant association between circulating IL-18 levels and carotid thickness 19 but not with another study by Chapman et al. evaluating men with different risk profile. 21 Finally, in a previous report in patients with unstable angina, it was observed that IL-18 level was accompanied by lower FMD. 17 This is not necessarily in contradiction of our results, since that study referred to a specific population with advance disease state.
limitations
Drugs were not discontinued prior to the study including these with potential effects on the levels of the target biochemical markers/mediators and arterial parameters, such as angiotensin-converting enzyme inhibitors/angiotensin-II type-1 receptor blockers and statins. 38 However, the association between IL-18 and arterial functional and structural parameters remained significant after adjustment for use of angiotensin-converting enzyme inhibitors/angiotensin-II type-1 receptor blockers and statins. The use of the Framingham risk equation in a non-American population, as our study group, may have resulted in some misclassification of risk.
In conclusion, this is the first study to demonstrate that concentration of IL-18 is independently associated with aortic stiffness and carotid thickness in individuals without manifest cardiovascular/atherosclerotic disease. This finding points out the important role of IL-18 as a marker of vascular damage, and implies a possible contribution of this compound to the process of arterial stiffening and subclinical atherosclerosis. IL-18 level may also serve as a risk stratification tool in this setting. Further investigations are warranted to determine possible causal relationships and to define whether increased IL-18 levels should call for more aggressive risk factor management.
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